RBP4 and metabolic dysfunction-associated steatotic liver disease: There were no statistically significant differences in circulating RBP4 levels between NAFLD patients and controls, according to a meta-analysis [273] (SMD]: 0.08; 95% CI: −0.21, 0.38).